Loading…
Maker of blood and plasma collection, processing devices and software used by blood centers, hospitals and plasma companies.
Maker of blood and plasma collection, processing devices and software used by blood centers, hospitals and plasma companies.
Places collection machines in plasma and blood centres, then earns repeatedly on the single-use sets each collection needs, a razor-and-blade model. A few large plasma-product makers' collection networks account for a large share of plasma sales. The hospital side sells blood-clot testing and surgical products.
Moat: narrow (switching costs, installed base, regulatory licence). Installed base of collection devices and disposables creates recurring, sticky consumable revenue.
Headquarters: Boston, Massachusetts · Founded: 1971 · Employees: 3,009
Size Haemonetics (HAE) is a United States Health Care company (Medical Specialties) with a market value of $5.46B, the 1124th largest of 3,117 United States companies the cockpit tracks. Shares closed at $119.93 on 6 Nov 2026.
Performance Over six months the shares gained 117.6%, against +25.2% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 0.4% over the last twelve months (peer median +6.8%); the operating margin is 18.4% (peer median 13.7%).
Valuation It trades at 21.6× forward earnings against a peer median of 19.9× (8th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.4 points above its cost of capital (7.5% WACC).
Backlog Backlog (remaining performance obligations) was $30.1M at 26 Sep 2026, down 15% on a year earlier — 0.0 years of trailing revenue. Backlog detail →
Credit Haemonetics has 1 bond outstanding ($700M).
Short interest Short interest is 7.5% of the free float (15 Oct 2026).
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.35B | $1.33B | $1.36B | $1.31B | $1.17B |
| Revenue growth | — | -2% | +4% | +12% | — |
| Gross profit | $756M | $743M | $715M | $677M | $590M |
| EBITDA | $358M | $356M | $338M | $305M | $261M |
| Net income | $96.3M | $97.3M | $168M | $118M | $115M |
| Free cash flow | $291M | $260M | $142M | $115M | $162M |
| Capital expenditure | $36.9M | $32.8M | $39.3M | $66.3M | $110M |
| Total debt | $1.17B | $1.27B | $1.28B | $874M | $773M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Haemonetics HAE | $5.46B | +118% | 0% | 18% | 21.6× | 10.9% |
| Terumo 4543.T | $23.4B | +25% | +14% | 17% | 24.6× | 8.7% |
| Grifols GRF.MC | $7.49B | +23% | 0% | 16% | 13.0× | 6.8% |
| CSL CSL.AX | $67.2B | +105% | -2% | 26% | 22.4× | 7.1% |
| Teleflex TFX | $6.39B | +13% | -14% | 11% | 16.8× | 17.8% |
| Baxter International BAX | $13.3B | +43% | +5% | 6% | 12.6× | 12.7% |
| Cerus CERS | $408M | -23% | +14% | -12% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | HAE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.4% | +10.3% | 5th lowest of 21 |
| 6-month return | +117.6% | +25.2% | 2nd highest of 21 |
| Distance from 52-week high | -9.1% | -10.4% | 8th highest of 21 |
| Revenue growth (TTM) | +0.4% | +6.8% | 8th lowest of 21 |
| Operating margin | 18.4% | 13.7% | 9th highest of 21 |
| Forward P/E | 21.6× | 19.9× | 8th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 10.9% | 11.5% | 7th least demanding of 18 |
| Growth delivered (Del g) | +8.9% | +9.5% | 8th lowest of 18 |
| Hurdle (Req g minus delivered) | +2.0 pp | +1.7 pp | 9th most demanding of 18 |
| ROIC minus cost of capital | +3.4 pp | +2.5 pp | 9th highest of 21 |
| EV / EBITDA | 17.9× | 15.4× | 5th most expensive of 15 |
| Net debt / EBITDA | 2.6× | 0.9× | 6th most indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Haemonetics HAE | United States | $5.46B | +118% | 0% | 18% | 21.6× | 10.9% | +8.9% |
| GRAIL GRAL | United States | $5.42B | +67% | +23% | -323% | n/a | n/a | n/a |
| Merit Medical Systems MMSI | United States | $5.23B | +42% | +9% | 14% | 19.4× | 12.2% | +9.5% |
| DiaSorin DIA.MI | Italy | $5.00B | +19% | -3% | 24% | 20.6× | 4.1% | +6.3% |
| APT Medical 688617.SS | China | $5.95B | +20% | +28% | 37% | 38.5× | 8.7% | +40.1% |
| LivaNova LIVN | United States | $4.96B | +25% | +12% | 13% | 19.9× | 11.5% | +8.2% |
| Asahi Intecc 7747.T | Japan | $6.28B | +13% | +21% | 31% | 26.0× | 13.6% | +18.8% |
| MiniMed MMED | United States | $4.70B | +44% | +14% | 14% | 25.5× | n/a | n/a |
| Ypsomed YPSN.SW | Switzerland | $6.35B | +30% | -2% | 25% | 30.1× | 11.5% | +12.6% |
| Teleflex TFX | United States | $6.39B | +13% | -14% | 11% | 16.8× | 17.8% | -4.7% |
| ConvaTec CTEC.L | United Kingdom | $6.44B | +22% | +2% | 16% | 16.7× | 15.6% | +4.6% |
| Sotera Health SHC | United States | $4.57B | +1% | +7% | 37% | 15.4× | 13.7% | +7.3% |
| Lantheus LNTH | United States | $6.57B | +8% | +2% | 19% | 17.5× | -0.5% | +35.3% |
| Intco Medical Technology 300677.SZ | China | $4.40B | -20% | +33% | 20% | 14.7× | -4.7% | -6.4% |
| ICU Medical ICUI | United States | $4.30B | +36% | -9% | 7% | 19.5× | 22.1% | +11.9% |
| Integer ITGR | United States | $4.30B | +44% | 0% | 9% | 18.8× | 19.6% | +11.5% |
| Jiangsu Yuyue Medical Equipment & Supply 002223.SZ | China | $4.26B | -1% | -1% | 13% | 20.4× | 5.1% | +3.4% |
| Cochlear COH.AX | Australia | $7.05B | +55% | -1% | 13% | 29.4× | 24.1% | +9.3% |
| Shenzhen New Industries Biomedical Engineering 300832.SZ | China | $7.11B | +25% | +7% | 43% | 25.5× | 2.1% | +15.7% |
| Bausch + Lomb BLCO.TO | Canada | $7.20B | +31% | +11% | 9% | 17.3× | 11.0% | +10.0% |
| CareDx CDNA | United States | $4.13B | +260% | +39% | 1% | 53.2× | n/a | n/a |
Haemonetics has 1 bond outstanding with $700M face value.
Haemonetics reported $30.1M of remaining performance obligations at 26 Sep 2026, down 15% from a year earlier and down 3% from the previous quarter. That is 0.0 years of trailing revenue already under contract. Book-to-bill last quarter: 1.00.